Loading, please wait ...


News Analytics

560358f0756982df3efcdc9ec67d06f96ea8534c 480x270 jpg?fit=crop&auto=format.
At a median follow-up of 15.6 months (IQR, 7.7-12.7) at the updated analysis, the median PFS observed with camerlizumab plus gemcitabine and cisplatin was 10.8 months (95% CI, 8.5-13.6) compared with 6.9 months (95% CI, 5.9-7.9) in the chemotherapy arm (HR, 0.51, 95% CI, 0.37-0.69).

Subject Matter

  • Healthcare 100.00%
    • Hospitals, doctors and medical care 100.00%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions